Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Impact BioMedical Inc. (IBO)
USD0.46
-0.02 (-4.17%)
US AMEX Healthcare Biotechnology
Address
1400 Broadfield Blvd. 77084
Houston, TX, US
Houston, TX, US
CEO
Frank D. Heuszel
Website
impactbiomedinc.com
IPO
2024-09-16
CIK 1834105 ISIN US45259L2051
Description
Houston, Texas-based Impact BioMedical Inc., founded in 2018, focuses on discovering and developing innovative products and therapeutic options for both specialty biopharmaceuticals and consumer healthcare markets. The company features several key technologies: its "Linebacker" platform utilizes small molecule electrophilically enhanced polyphenol compounds with potential applications in treating cancer, inflammatory diseases, and neurological conditions. Additionally, "Laetose" technology, a unique blend of sugar and inositol, is designed to counteract the inflammatory and metabolic responses usually triggered by sugar consumption. Impact BioMedical also creates "functional fragrance formulations," which are a series of fragrances incorporating specialized botanical ingredients for antimicrobial purposes, or as active additives in items like insect repellents, cleaning products, personal care items, and fabrics. Rounding out its offerings is the "Equivir/Equivir G" technology, a distinctive mix of polyphenols that has exhibited antiviral properties, suitable for use in health supplements and medications.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.46
-0.02 (-4.17%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
86.4K
Beta
2.71
Float Shares
12.17M
Free Float %
97.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.91% | -7.69% | -16.84% | +30.57% | +14.08% | +15.21% | +5.94% | -78.29% | -78.29% | -78.29% | -78.29% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.46
DCF (Levered)
0.00
-100.0%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Quality scores
Altman Z-Score
-3.43
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-98.6%
-
EPS growth Biotechnology: +29.7%-3,700.0% Q1'26: +80.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-31,640.6% Q1'26: +1,414.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-42,678.1% Q1'26: +0.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-87.8% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-24.4% ★ Q1'26: +793.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-513.9K
OE per share TTM
-0.05
Owner's Yield
-0.82%
Maintenance CapEx ratio
0.00%
Maint CapEx / Avg PPE
0.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
12
Total invested
978.1K
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
12
-10 vs prev Q
New positions
5
Closed positions
15
Increased
7
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 814.9K +712.0K (+691.9%) | 411.5K +343.1K (+501.4%) | 6.69% +5.843 pp | 0.00% +0.000 pp | USD0.53 -3.8% | 4 qtrs — |
| 2 | BLACKROCK, INC. | 259.9K +7.2K (+2.9%) | 131.3K -36.7K (-21.9%) | 2.13% +0.059 pp | 0.00% +0.000 pp | USD0.67 -23.9% | 4 qtrs — |
| 3 | MILLENNIUM MANAGEMENT LLC | 137.8K +137.8K (+100.0%) | 69.6K +69.6K (+100.0%) | 1.13% +1.131 pp | 0.00% +0.000 pp | USD0.51 +0.0% | 1 qtrs NEW |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 74.4K +29.3K (+64.9%) | 37.6K +7.6K (+25.3%) | 0.61% +0.240 pp | 0.00% +0.000 pp | USD0.80 -36.3% | 5 qtrs — |
| 5 | TWO SIGMA INVESTMENTS, LP | 39.8K +8.3K (+26.4%) | 20.1K -828.0 (-4.0%) | 0.33% +0.068 pp | 0.00% +0.000 pp | USD0.62 -17.7% | 3 qtrs — |
| 6 | TWO SIGMA SECURITIES, LLC | 22.7K -5.7K (-20.2%) | 11.5K -7.4K (-39.4%) | 0.19% -0.047 pp | 0.00% -0.001 pp | USD0.66 -22.7% | 2 qtrs — |
| 7 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 16.5K -4.5K (-21.3%) | 8.3K -5.6K (-40.2%) | 0.14% -0.037 pp | 0.00% +0.000 pp | USD0.65 -21.5% | 3 qtrs — |
| 8 | JANE STREET GROUP, LLC | 14.1K +14.1K (+100.0%) | 7.1K +7.1K (+100.0%) | 0.12% +0.116 pp | 0.00% +0.000 pp | USD0.50 +2.0% | 1 qtrs NEW |
| 9 | HRT FINANCIAL LP | 13.5K +13.5K (+100.0%) | 6.0K +6.0K (+100.0%) | 0.11% +0.111 pp | 0.00% +0.000 pp | USD0.50 +2.0% | 6 qtrs — |
| 10 | STATE STREET CORP | 11.8K +— (+0.0%) | 6.0K -1.9K (-24.0%) | 0.10% +0.000 pp | 0.00% +0.000 pp | USD1.42 -64.1% | 5 qtrs — |
| 11 | NORTHERN TRUST CORP | 10.2K +10.2K (+100.0%) | 5.2K +5.2K (+100.0%) | 0.08% +0.084 pp | 0.00% +0.000 pp | USD0.50 +2.0% | 1 qtrs NEW |
| 12 | MASON & ASSOCIATES INC | 10.0K +— (+0.0%) | 5.1K -1.6K (-24.0%) | 0.08% +0.000 pp | 0.00% 0.000 pp | USD0.66 -22.7% | 2 qtrs — |
| 13 | MORGAN STANLEY | 9.3K +— (+0.0%) | 4.7K -1.5K (-24.0%) | 0.08% +0.000 pp | 0.00% +0.000 pp | USD0.66 -22.7% | 6 qtrs — |
| 14 | UBS GROUP AG | 2.2K -17.9K (-89.2%) | 1.1K -12.3K (-91.8%) | 0.02% -0.147 pp | 0.00% +0.000 pp | USD0.80 -36.3% | 6 qtrs — |
| 15 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.4K -16.0 (-1.1%) | 720.00 -239.0 (-24.9%) | 0.01% 0.000 pp | 0.00% +0.000 pp | USD1.45 -64.8% | 5 qtrs — |
| 16 | BANK OF AMERICA CORP /DE/ | 924.00 +756.0 (+450.0%) | 467.00 +356.0 (+320.7%) | 0.01% +0.006 pp | 0.00% +0.000 pp | USD0.56 -8.9% | 6 qtrs — |
| 17 | WELLS FARGO & COMPANY/MN | 224.00 -29.0 (-11.5%) | 113.00 -55.0 (-32.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD0.69 -26.1% | 6 qtrs — |
| 18 | NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | 86.00 +— (+0.0%) | 43.00 -14.0 (-24.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.44 -64.6% | 5 qtrs — |
| 19 | DANSKE BANK A/S | 3.00 +— (+0.0%) | 2.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 -74.5% | 6 qtrs — |
| 20 | SIGNATURE RESOURCES CAPITAL MANAGEMENT, LLC | 4.00 +— (+0.0%) | 2.00 -1.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.75 -32.0% | 4 qtrs — |
| 21 | GROUP ONE TRADING, L.P. | 1.00 +— (+0.0%) | 1.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 -74.5% | 6 qtrs — |
| 22 | CITIGROUP INC | 1.00 -3.4K (-100.0%) | 1.00 -2.3K (-100.0%) | 0.00% -0.028 pp | 0.00% +0.000 pp | USD— | 3 qtrs — |
| 23 | BARCLAYS PLC | — -1.1K (-100.0%) | — -2.2K (-100.0%) | 0.00% -0.009 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 24 | FMR LLC | — -36.0 (-100.0%) | — -24.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 9 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 399.1K | 0.05% |
| 2 | iShares Core MSCI All-Country World ex Canada Index ETF XAW.TO | 0.00% | — | 0.22% |
| 3 | iShares Core Conservative Balanced ETF Portfolio XCNS.TO | 0.00% | — | 0.19% |
| 4 | iShares Core Equity ETF Portfolio XEQT.TO | 0.00% | — | 0.20% |
| 5 | iShares Core Balanced ETF Portfolio XBAL.TO | 0.00% | — | 0.19% |
| 6 | iShares Core Income Balanced ETF Portfolio XINC.TO | 0.00% | — | 0.19% |
| 7 | iShares Core Growth ETF Portfolio XGRO.TO | 0.00% | — | 0.20% |
| 8 | iShares Core S&P Total U.S. Stock Market ETF ITOT | 0.00% | — | 0.03% |
| 9 | iShares Core S&P U.S. Total Market Index ETF XUU.TO | 0.00% | — | 0.07% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
50.0K
Cash buys
—
Cash sales
1.00
Net activity
-50,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-27 | Macko Todd D | Officer | S-Sale | D | Common Stock | 43,400 | 0.56 | 24.4K | 155,122 | D | ↗ |
| 2026-03-25 | Macko Todd D | Officer | S-Sale | D | Common Stock | 1,600 | 0.60 | 961.28 | 198,122 | D | ↗ |
| 2026-03-23 | Grady Jason | Director | S-Sale | D | Common Stock | 50,000 | 0.65 | 32.5K | 250,182 | D | ↗ |
| 2025-05-27 | DSS, INC. | 10% Owner | S-Sale | D | Common Stock | 45,400 | 0.54 | 24.5K | 545,024 | D | ↗ |
| 2025-05-22 | DSS, INC. | 10% Owner | S-Sale | D | Common Stock | 115,600 | 0.55 | 63.5K | 590,424 | D | ↗ |
| 2025-04-04 | DSS, INC. | 10% Owner | S-Sale | D | Common Stock | 890,800 | 0.95 | 845.0K | 161,100 | D | ↗ |
| 2025-04-04 | Chan Heng Fai Ambrose | Director / 10% Owner | S-Sale | D | Common stock | 180,000 | 0.96 | 172.8K | 0 | I | ↗ |
| 2025-04-03 | Chan Heng Fai Ambrose | Director | S-Sale | D | Common stock | 351,555 | 0.50 | 174.0K | 0 | I | ↗ |
| 2025-04-02 | Chan Heng Fai Ambrose | Director / 10% Owner | S-Sale | D | Common stock | 2,349 | 0.67 | 1.6K | 351,555 | I | ↗ |
| 2025-04-01 | Chan Heng Fai Ambrose | Director / 10% Owner | S-Sale | D | Common Stock | 650,000 | 1.45 | 940.6K | 1,910,976 | I | ↗ |
| 2025-03-31 | Chan Heng Fai Ambrose | Director / 10% Owner | S-Sale | D | Common Stock | 300,000 | 1.03 | 308.4K | 1,253,904 | I | ↗ |
| 2025-03-27 | DSS, INC. | 10% Owner | S-Sale | D | Common Stock | 47,681 | 2.50 | 119.3K | 1,051,800 | D | ↗ |
| 2025-03-26 | DSS, INC. | 10% Owner | S-Sale | D | Common Stock | 48,281 | 3.13 | 151.1K | 1,109,339 | D | ↗ |
| 2025-03-21 | DSS, INC. | 10% Owner | S-Sale | D | Common Stock | 166,600 | 3.30 | 549.8K | 0 | I | ↗ |
| 2025-03-20 | DSS, INC. | 10% Owner | P-Purchase | A | Common Stock | 200 | 1.55 | 310.00 | 53,280 | I | ↗ |
| 2024-12-05 | Heuszel Frank D | Director / Officer | P-Purchase | A | Common Stock | 500 | 2.26 | 1.1K | 97,344 | D | ↗ |
| 2024-12-02 | DSS, INC. | 10% Owner | S-Sale | D | Common Stock | 20 | 2.90 | 58.00 | 53,080 | I | ↗ |
| 2024-11-27 | Heuszel Frank D | Director / Officer | P-Purchase | A | Common Stock | 500 | 2.61 | 1.3K | 96,844 | D | ↗ |
| 2024-11-26 | Heuszel Frank D | Director / Officer | P-Purchase | A | Common Stock | 500 | 2.59 | 1.3K | 96,344 | D | ↗ |
| 2024-11-18 | DSS, INC. | 10% Owner | S-Sale | D | Common Stock | 5,000 | 3.02 | 15.1K | 53,100 | I | ↗ |
| 2024-11-13 | DSS, INC. | 10% Owner | S-Sale | D | Common Stock | 200 | 2.80 | 560.00 | 58,100 | I | ↗ |
| 2024-11-12 | DSS, INC. | 10% Owner | S-Sale | D | Common Stock | 500 | 2.76 | 1.4K | 58,300 | I | ↗ |
| 2024-09-18 | DSS, INC. | 10% Owner | P-Purchase | A | Common Stock | 1,000 | 2.33 | 2.3K | 58,800 | — | ↗ |
| 2024-09-17 | DSS, INC. | 10% Owner | P-Purchase | A | Common Stock | 7,800 | 2.40 | 18.7K | 57,800 | — | ↗ |
| 2024-09-16 | Zimmerman Christian Thomas | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-16 | Suseck Mark | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-16 | Sims Melissa Kaye | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-16 | Macko Todd D | Officer | — | D | Common Stock | 0 | 0.00 | — | 121 | — | ↗ |
| 2024-09-16 | Keene David K | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-16 | Hibbert Castel Berisford | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-09-16 | Heuszel Frank D | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 95,475 | — | ↗ |
| 2024-09-16 | Grady Jason | Director | — | D | Common Stock | 0 | 0.00 | — | 182 | — | ↗ |
| 2024-09-16 | DSS, INC. | 10% Owner | P-Purchase | A | Common Stock | 50,000 | 2.69 | 134.5K | 50,000 | — | ↗ |
| 2024-09-16 | Chan Heng Fai Ambrose | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 4,568,165 | — | ↗ |
| 2024-09-16 | Brownell Elise | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-21.4K
Shares Outstanding
12.50M
Executive compensation
Executive compensation (annual)
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2025-09-22 | DEF 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Frank D. Heuszel | Chairman & Chief Executive Officer | 302.0K | male |
| Mark J. Suseck | Chief Operating Officer | 293.8K | male |
| Todd D. Macko | Chief Financial Officer, Secretary & Treasurer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IBO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
